Abstract
Diabetes Technology Society hosted its annual Diabetes Technology Meeting on November 12 to November 14, 2020. This meeting brought together speakers to cover various perspectives about the field of diabetes technology. The meeting topics included artificial intelligence, digital health, telemedicine, glucose monitoring, regulatory trends, metrics for expressing glycemia, pharmaceuticals, automated insulin delivery systems, novel insulins, metrics for diabetes monitoring, and discriminatory aspects of diabetes technology. A live demonstration was presented.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 916-960 |
| Number of pages | 45 |
| Journal | Journal of Diabetes Science and Technology |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2021 |
Funding
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TS, JZ, BWB, JKR, GC, YP, CEM, SK, BHG, and UM have nothing to disclose. JLS has had research support from the NIH, JDRF, and the Helmsley Charitable Trust and her institution has had research support from Medtronic and Insulet. JLS serves as a consultant to Cecelia Health, Lexicon, Lilly, Insulet, Medtronic, and Sanofi. She also is a member of the advisory board for Bigfoot Biomedical, Cecelia Health, Insulet, Medtronic, and the T1D Fund. JC is a shareholder of Pacific Diabetes Technologies, has received research support from Dexcom, and participates in the advisory board for Insulet. JP has been an advisory board member for BD and Medtronic, and a speaker for Insulet. JE’s efforts were supported by the Food and Drug Administration under award number P50FD006425 for The West Coast Consortium for Technology & Innovation in Pediatrics. The funding source had no involvement in the development of this manuscript or in the decision to submit the paper for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the FDA. LHM is a consultant and speaker for Tandem Diabetes, a speaker for Dexcom, and a consultant for Capillary Biomedical. TH’s employer has received research grants from Adocia, Biocon, Eli Lilly, Gan Lee Pharmaceuticals, Mylan, Novo Nordisk and Sanofi. TH has also received speaker honoraria from Novo Nordisk, and is an advisory board member for Novo Nordisk. RJG is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) under award numbers P30DK111024-04S2 and 5K23DK123384-02. RJG received unrestricted research support (to Emory University) for investigator-initiated studies from Novo Nordisk, Eli Lilly and Dexcom, and consulting fees from Abbott Diabetes Care, Sanofi, Novo Nordisk, Eli Lilly and Valeritas. DCK is a consultant for EOFlow, Fractyl, Lifecare, Novo, Roche, Samsung, and Thirdwayv. For contributing key points to this report and reviewing the manuscript, we would like to thank: Pratik Agrawal, MS, David Ahn, MD, Mark Arnold, PhD, Guillermo Arreaza-Rubin, MD, Timothy S. Bailey, MD, FACE, CPI, Richard Bergenstal, MD, Kåre I. Birkeland, MD, Bruce Bode, MD, Bruce Buckingham, MD, Chris Boulton, BSc, Andrew Bremer, MD, PhD, Marc Breton, PhD, Elizabeth Burner, MD, MPH, MSci, Celeste Campos-Castillo, PhD, Eda Cengiz, MD, FAAP, MHS, Christian Cerrada, PhD, Pratik Choudhary, MBBD, MRCP, MD, Faz Chowdhury, PhD, Ali Cinar, PhD, Mark Clements, MD, PhD, Sam Collaudin, PhD, jMBA, Keesha M. Crosby, MS, Ronald Dixon, MD, Frank Doyle, PhD, CPGS, Steven Edelman, MD, Chiara Fabris, PhD, Alexander Fleming, MD, Guido Freckmann, MD, Karl Friedl, PhD, COL(ret), Brian Frier, BSc (Hons), MD, FRCP(Edin), FRCP(Glas), Robert Gabbay, MD, PhD, Avner Gal, MBA, MSCEE, MSc, Bastiaan de Galan, MD, PhD, Wei Gao, PhD, Dan Goldner, PhD, Gerold Grodsky, PhD, Alberto Gutierrez, PhD, Lutz Heinemann, PhD, H. Michael Heise, PhD, Rolf Hinzmann, MD, PhD, Irl Hirsch, MD, Thanh Hoang, DO, David Horwitz, MD, PhD, Roman Hovorka, PhD, FMedSci, Peter G. Jacobs, PhD, Jeffrey Joseph, DO, Francine Kaufman, MD, David Kerr, MBChB, DM, FRCP, FRCPE, Leslie Klaff, MD, PhD, David Kleidermacher, BS, Craig Kollman, PhD, Boris Kovatchev, PhD, Piotr Ladyzynski, PhD, Jordan Messler, MD, SFHM, FACP, Bijan Najafi, PhD, Aaron Neinstein, MD, Anne Peters, MD, FACP, CDE, Fazlyn Petersen, PhD, Andreas Pfützner, MD, PhD, Athena Philis-Tsimikas, MD, Moshe Phillip, MD, Kenneth Quinto, MD, MPH, Mihailo Rebec, PhD, Eun-Jung Rhee, MD, PhD, Mercedes Rigla, MD, PhD, David Rodbard, MD, Julio Rosenstock, MD, Robert Schumm, MBA, Naomi Schwartz, MS, Suzanne Schwartz, MD, MBA, Peter Simpson, MS, Akhil Srinivasan, PhD, Timothy Stenzel, MD, PhD, Andreas Stuhr, MD, MBA, Marc Taub, PhD, Matthew Taylor, CFA, Anders Dyhr Toft, MD, PhD, eMBA, Hubert Vesper, PhD, Hope Warshaw, MMSc, RD, CDCES, BC-ADM, Christopher Wilson, PhD, Howard Wolpert, MD, Yiduo Wu, PhD, and Dessi Zaharieva, PhD. We thank Annamarie Sucher-Jones for her expert editorial assistance. The author(s) received no financial support for the research, authorship, and/or publication of this article.
Keywords
- diabetes
- glucose
- insulin
- meeting
- software
- technology
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Bioengineering
- Biomedical Engineering
